Alizyme plc
Alizyme is fighting the good fight against ills brought on by the good life. The development-stage biotechnology company licenses drug candidates and develops them. It targets conditions prevalent primarily in industrialized countries, including obesity, type 2 diabetes (often associated with obesity), and ulcerative colitis. Alizyme is focused on developing a family of lipase inhibitors, which prevent the body from absorbing fat. In addition to its pipeline of treatments for lifestyle-related conditions, the company is developing a drug for mucositis, cancer therapy-induced damage to the gastrointestinal tract.
Contact Details
Office Address
Alizyme plc
Granta Park
Great Abington, Cambridge, UK CB216GX
Phone: +44-1223-896-000
Fax: +44-1223-896-001
Executives
Chairman
Alan Goodman